Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle
Mandate

Vinge advises Lantmännen in conjunction with acquisition from Tate&Lyle

March 28, 2019 M&A

Vinge has advised Lantmännen in connection with its acquisition of British Tate&Lyle’s Swedish oat production operations.

The acquisition is a part of Lantmännen’s continued focus on additional processing of oats to, inter alia, the food manufacturing industry.

Vinge’s team consisted of partner Christina Kokko together with, among others, associates Karl Klackenberg and David Lundahl (M&A), partner Johan Cederblad and associate Hampus Olsson (Environmental/Permits) as well as associates Hedvig Ekdahl (Commerical Agreements), Lisa Ullman (Employment), Karolina Cohrs (Real Property) and Klara Secher (IP).
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025